3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
10
Nivolumab
5
Granulocyte Colony-Stimulating Factor
4
atezolizumab
3
Ipilimumab
3
Ifosfamide
3
Etoposide
3
tislelizumab
2
sargramostim
2
durvalumab
2
Thiotepa
2
Paclitaxel
2
Mesna
2
Melphalan
2
Filgrastim
2
Docetaxel
2
Cyclophosphamide
2
Carboplatin
2
Busulfan
2
tazemetostat
1
spartalizumab
1
regorafenib
1
pegylated granulocyte colony-stimulating factor
1
obinutuzumab
1
niraparib
1
naptumomab estafenatox
1
milademetan
1
etoposide phosphate
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Blood Component Removal
×
Other solid neoplasm
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled